Provided by Tiger Trade Technology Pte. Ltd.

GeneDx Holdings

90.15
-0.5200-0.57%
Post-market: 90.250.1000+0.11%19:59 EST
Volume:627.87K
Turnover:56.61M
Market Cap:2.61B
PE:1.23K
High:94.88
Open:90.08
Low:89.00
Close:90.67
52wk High:170.87
52wk Low:55.17
Shares:28.90M
Float Shares:19.94M
Volume Ratio:0.83
T/O Rate:3.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0735
EPS(LYR):-1.9444
ROE:0.84%
ROA:1.61%
PB:8.92
PE(LYR):-46.37

Loading ...

BRIEF-Time Names Genedx CEO Katherine Stueland To The 2026 Time100 Health List Of The World’S Most Influential Leaders In Health

Reuters
·
Feb 11

Time Names GeneDx CEO Katherine Stueland to the 2026 Time100 Health List of the World’s Most Influential Leaders in Health

THOMSON REUTERS
·
Feb 11

Wells Fargo Upgrades GeneDx Holdings to Overweight From Equalweight

MT Newswires Live
·
Feb 09

GeneDx Holdings Corp. : Wells Fargo Raises to Overweight From Equal Weight

THOMSON REUTERS
·
Feb 09

U.S. RESEARCH ROUNDUP-Align Technology, Biogen, Citigroup

Reuters
·
Feb 09

GeneDx COO Bryan Dechairo Reports Disposal of Common Shares

Reuters
·
Feb 07

GeneDx Holdings Corp. to Release Fourth Quarter Financial Results

Reuters
·
Feb 03

Analysts Are Bullish on Top Healthcare Stocks: Immutep Ltd (PRRUF), GeneDx Holdings (WGS)

TIPRANKS
·
Feb 02

Cathie Wood’s ARK Investment buys 91.8K shares of GeneDx today

TIPRANKS
·
Jan 31

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

GlobeNewswire
·
Jan 27

GeneDx Holdings (WGS) Valuation After Strong 2025 Outlook And New Genomics Growth Initiatives

Simply Wall St.
·
Jan 16

Health Minister Responds to Reports of Two Super Flu Cases in Bali

Tempo
·
Jan 15

Stock Track | GeneDx Holdings Plummets 5.07% Intraday Amid Mixed Analyst Opinions

Stock Track
·
Jan 13

GeneDx Shares Down 2.5% After Announcing Preliminary Q4 Results, 2026 Outlook

THOMSON REUTERS
·
Jan 12

GeneDx Reports Preliminary Q4 Revenue; Issues 2026 Revenue Guidance

MT Newswires Live
·
Jan 12

Genedx Holdings Corp. unveils presentation highlighting advances in rare disease diagnosis and genomics-driven healthcare

Reuters
·
Jan 12

GeneDx reports preliminary Q4 revenue $121M, consensus $120.49M

TIPRANKS
·
Jan 12

GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth

Reuters
·
Jan 12

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

THOMSON REUTERS
·
Jan 12

GeneDx Holdings Corp - Expects 2025 Revenues of $427 Mln

THOMSON REUTERS
·
Jan 12